- Home
- FFA vs KMDA Comparison
FFA vs KMDA Comparison
Compare FFA & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFA
- KMDA
- Stock Information
- Founded
- FFA 2004
- KMDA 1990
- Country
- FFA United States
- KMDA Israel
- Employees
- FFA N/A
- KMDA N/A
- Industry
- FFA Investment Managers
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- FFA Finance
- KMDA Health Care
- Exchange
- FFA Nasdaq
- KMDA Nasdaq
- Market Cap
- FFA 416.1M
- KMDA 430.1M
- IPO Year
- FFA N/A
- KMDA N/A
- Fundamental
- Price
- FFA $21.00
- KMDA $7.18
- Analyst Decision
- FFA
- KMDA Strong Buy
- Analyst Count
- FFA 0
- KMDA 2
- Target Price
- FFA N/A
- KMDA $13.00
- AVG Volume (30 Days)
- FFA 26.1K
- KMDA 48.5K
- Earning Date
- FFA 01-01-0001
- KMDA 08-13-2025
- Dividend Yield
- FFA 6.72%
- KMDA 2.77%
- EPS Growth
- FFA N/A
- KMDA 27.97
- EPS
- FFA N/A
- KMDA 0.32
- Revenue
- FFA N/A
- KMDA $169,517,000.00
- Revenue This Year
- FFA N/A
- KMDA $14.51
- Revenue Next Year
- FFA N/A
- KMDA $9.31
- P/E Ratio
- FFA N/A
- KMDA $22.07
- Revenue Growth
- FFA N/A
- KMDA 9.67
- 52 Week Low
- FFA $15.84
- KMDA $5.17
- 52 Week High
- FFA $19.30
- KMDA $9.16
- Technical
- Relative Strength Index (RSI)
- FFA 56.65
- KMDA 48.39
- Support Level
- FFA $20.45
- KMDA $7.17
- Resistance Level
- FFA $21.24
- KMDA $7.85
- Average True Range (ATR)
- FFA 0.19
- KMDA 0.20
- MACD
- FFA -0.01
- KMDA 0.00
- Stochastic Oscillator
- FFA 61.24
- KMDA 50.46
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.